These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 22075648

  • 1. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension.
    Ginsberg Y, Lindefors N.
    Br J Psychiatry; 2012 Jan; 200(1):68-73. PubMed ID: 22075648
    [Abstract] [Full Text] [Related]

  • 2. Long-Term Treatment Outcome in Adult Male Prisoners With Attention-Deficit/Hyperactivity Disorder: Three-Year Naturalistic Follow-Up of a 52-Week Methylphenidate Trial.
    Ginsberg Y, Långström N, Larsson H, Lindefors N.
    J Clin Psychopharmacol; 2015 Oct; 35(5):535-43. PubMed ID: 26284932
    [Abstract] [Full Text] [Related]

  • 3. Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate.
    Ginsberg Y, Hirvikoski T, Grann M, Lindefors N.
    Eur Arch Psychiatry Clin Neurosci; 2012 Dec; 262(8):705-24. PubMed ID: 22526730
    [Abstract] [Full Text] [Related]

  • 4. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI, Bijlenga D, Boonstra AM, Breuk M, Pardoen WF, Beekman AT, Kooij JJ.
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [Abstract] [Full Text] [Related]

  • 5. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder.
    Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK.
    J Clin Psychiatry; 2007 Jan; 68(1):93-101. PubMed ID: 17284136
    [Abstract] [Full Text] [Related]

  • 6. Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study.
    Asherson PJ, Johansson L, Holland R, Bedding M, Forrester A, Giannulli L, Ginsberg Y, Howitt S, Kretzschmar I, Lawrie SM, Marsh C, Kelly C, Mansfield M, McCafferty C, Khan K, Müller-Sedgwick U, Strang J, Williamson G, Wilson L, Young S, Landau S, Thomson LDG.
    Br J Psychiatry; 2023 Jan; 222(1):7-17. PubMed ID: 35657651
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S.
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A, Richard C, Prinzo R, Binder C.
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [Abstract] [Full Text] [Related]

  • 12. Methylphenidate for prison inmates with ADHD: yes or no?
    Cortese S.
    Br J Psychiatry; 2023 Jan; 222(1):4-6. PubMed ID: 36263739
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.
    Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, Adler LA, Weiss RD, Leimberger JD, Lewis DF, Dorer EM.
    J Clin Psychiatry; 2010 Dec; 71(12):1680-8. PubMed ID: 20492837
    [Abstract] [Full Text] [Related]

  • 17. Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate.
    Buitelaar JK, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, Casas M, van Oene JC, Schäuble B, Trott GE.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar 30; 35(2):554-60. PubMed ID: 21185347
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Protocol of a monocentric, double-blind, randomized, superiority, controlled trial evaluating the effect of in-prison OROS-methylphenidate vs. placebo treatment in detained people with attention-deficit hyperactivity disorder (BATIR).
    Baggio S, Billieux J, Dirkzwager A, Iglesias K, Moschetti K, Perroud N, Schneider M, Vernaz N, Wolff H, Heller P.
    Trials; 2024 Jan 04; 25(1):23. PubMed ID: 38178233
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.